ALNY · Healthcare
ALNYLAM PHARMACEUTICALS INC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
39
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in ALNYLAM PHARMACEUTICALS INC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$35.7B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ALNYLAM PHARMACEUTICALS INC
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran…
Who's behind the signal
Every informed buyer we can see on ALNY, across all three feeds.
Hedge funds · 7
AQR Capital Management
Increased +24%
D.E. Shaw & Co
Increased +123%
Bridgewater Associates (Dalio)
Increased +152%
Gotham Asset Mgmt (Greenblatt)
Increased +41%
Baillie Gifford & Co
Decreased −7%
Millennium Management (Englander)
Decreased −86%
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ALNYLAM PHARMACEUTICALS INC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
0
New positions
4
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+24%
0.2% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+123%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.3×
% of portfolio
0.1%
Position change
+152%
0.1% of Bridgewater Associates's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+41%
0.1% of Gotham Asset Mgmt's portfolio
Trust weight: 1.4×
% of portfolio
0.9%
Position change
−7%
0.9% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−86%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−83%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ALNYLAM PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ALNYLAM PHARMACEUTICALS INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime